Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)

• Company Description    Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. Number of Employees: 169

• Price / Volume Information    Yesterday's Closing Price: $14.44 Daily Weekly Monthly 20 Day Moving Average: 445,402 shares Shares Outstanding: 40.62 (millions) Market Capitalization: $586.48 (millions) Beta: 1.26 52 Week High: $72.37 52 Week Low: $9.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.87% 2.24% 12 Week 2.63% -13.39% Year To Date -8.78% -14.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1050 WALTHAM STREET SUITE 302 - LEXINGTON,MA 02421 USA ph: 617-314-6297 fax: - jfrantz@kerostx.com http://www.kerostx.com

• General Corporate Information    Officers Jasbir Seehra - Chief Executive Officer Keith Regnante - Chief Financial Officer Jean-Jacques Bienaime - Director Nima Farzan - Director Carl Gordon - Director Peer Information Keros Therapeutics, Inc. (CORR.) Keros Therapeutics, Inc. (RSPI) Keros Therapeutics, Inc. (CGXP) Keros Therapeutics, Inc. (BGEN) Keros Therapeutics, Inc. (GTBP) Keros Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 492327101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 40.62 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $586.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 26.81% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.80 Price/Cash Flow: - Price / Sales: 2.73 EPS Growth vs. Year Ago Period: 399.17% vs. Previous Quarter: 417.54% Sales Growth vs. Year Ago Period: 254,413.27% vs. Previous Quarter: 6,844.31% ROE 06/30/25 - - 03/31/25 - 0.75 12/31/24 - -37.86 ROA 06/30/25 - - 03/31/25 - 0.69 12/31/24 - -35.08 Current Ratio 06/30/25 - - 03/31/25 - 19.29 12/31/24 - 21.45 Quick Ratio 06/30/25 - - 03/31/25 - 19.29 12/31/24 - 21.45 Operating Margin 06/30/25 - - 03/31/25 - 1.96 12/31/24 - -5,277.55 Net Margin 06/30/25 - - 03/31/25 - 1.96 12/31/24 - -5,277.55 Pre-Tax Margin 06/30/25 - - 03/31/25 - 6.78 12/31/24 - -5,269.10 Book Value 06/30/25 - - 03/31/25 - 17.95 12/31/24 - 14.11 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©